- Research article
- Open Access
High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study
BMC Gastroenterology volume 20, Article number: 128 (2020)
Because of high-risk behaviours, sedentary lifestyle and side effects of medications, psychiatric patients are at risk of viral hepatitis, alcohol-related liver disease and non-alcoholic fatty liver disease. We aimed to study the incidence of hepatocellular carcinoma (HCC) and cirrhotic complications in psychiatric patients.
We identified consecutive adult patients in all public hospitals and clinics in Hong Kong with psychiatric diagnoses between year 2003 and 2007 using the Clinical Data Analysis and Reporting System, which represents in-patient and out-patient data of approximately 80% of the 7.4-million local population. The patients were followed for liver-related events (HCC and cirrhotic complications) and deaths until December 2017. Age- and sex-standardized incidence ratio (SIR) of HCC in psychiatric patients to the general population was estimated by Poisson model.
We included 105,763 psychiatric patients without prior liver-related events in the final analysis. During a median (interquartile range) follow-up of 12.4 (11.0–13.7) years, 1461 (1.4%) patients developed liver-related events; 472 (0.4%) patients developed HCC. Compared with the general population, psychiatric patients had increased incidence of HCC (SIR 1.42, 95% confidence interval [CI] 1.28–1.57, P < 0.001). The SIR was highest in patients with drug-induced (SIR 3.18, 95% CI 2.41–4.11, P < 0.001) and alcohol-induced mental disorders (SIR 2.98, 95% CI 2.30–3.81, P < 0.001), but was also increased in patients with psychotic disorders (SIR 1.39, 95% CI 1.16–1.65, P < 0.001) and mood disorders (SIR 1.16, 95% CI 1.00–1.34, P = 0.047). Liver disease was the fifth most common cause of death in this population, accounting for 595 of 10,614 (5.6%) deaths. Importantly, 569 (38.9%) patients were not known to have liver diseases at the time of liver-related events. The median age at HCC diagnosis (61 [range 26–83] years) was older and the median overall survival (8.0 [95% CI 5.0–10.9] months) after HCC diagnosis was shorter in this cohort of psychiatric patients than other reports from Hong Kong.
HCC, cirrhotic complications, and liver-related deaths are common in psychiatric patients, but liver diseases are often undiagnosed. More efforts are needed to identify liver diseases in the psychiatric population so that treatments and screening for HCC and varices can be provided to patients in need.
Chronic liver diseases and the resultant portal hypertension and hepatocellular carcinoma (HCC) are among the leading causes of death worldwide . Psychiatric illness is also highly prevalent and accounts for 13% of disability-adjusted life-years globally . Patients with psychiatric illness are at risk of different liver diseases. Alcohol and substance abuse predisposes patients to alcohol-related liver disease and hepatitis C virus infection . Excessive alcohol consumption also aggravates existing liver diseases such as chronic viral hepatitis.
Moreover, non-alcoholic fatty liver disease (NAFLD) affects a quarter of the global adult population and has become one of the leading causes of cirrhosis and HCC in the Western world [4,5,6]. Patients with psychiatric illness often have obesity and metabolic syndrome . A number of potential mechanisms have been proposed, including activation of the hypothalamus-pituitary-adrenal axis through acute stress response, abnormalities in the autonomic nervous system, systemic inflammation and oxidative stress, and changes in appetite-controlling hormones. Patients with psychiatric illness tend to lead a more sedentary lifestyle. Second generation antipsychotics, antidepressants and mood stabilizers may be obesogenic and/or hepatotoxic . Some genes (e.g. CLOCK genetic variants) affect both metabolism and mental illness [9, 10]. Besides, diabetes, cardiovascular disorders and sleep and/or circadian disruptions are common in psychiatric illness.
Accordingly, a study by the United States Veterans Integrated Services Network showed that 22.4% of patients with schizophrenia had one or more liver diseases . NAFLD patients with depression also have more severe liver histology . However, liver biopsy is performed in a highly selected population, which cannot represent the average patients with psychiatric illness. The magnitude of liver-related morbidity and mortality among psychiatric patients is largely unknown.
In addition, comorbid illnesses are often underdiagnosed in psychiatric patients . Currently, effective treatments for many chronic liver diseases exist and may reduce the risk of cirrhotic complications and HCC [14, 15]. A better understanding of the epidemiology of chronic liver diseases among patients with psychiatric illness would allow policymakers to determine the value of screening and formulate an action plan. In this project, we studied a large territory-wide Hong Kong cohort and determined the incidence of HCC and cirrhotic complications in patients with psychiatric illness.
Study design and data source
This is a retrospective cohort study based on data retrieved from the Clinical Data Analysis and Reporting System (CDARS) . CDARS is an electronic healthcare database managed by the Hospital Authority, Hong Kong. CDARS includes in-patient and out-patient data from all public healthcare services in Hong Kong, which covers approximately 80% of the 7.4-million local population . All clinical information captured in CDARS including patients’ demographic, diagnoses, procedures, drug prescription and dispensing history, and laboratory results were anonymised to ensure confidentiality. Death date and causes of death in CDARS are extracted from the death registry of the Immigration Department of Hong Kong . Multiple territory-wide studies were conducted based on CDARS [19,20,21,22,23]. Diagnosis and procedures in CDARS were recorded by the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding. The ICD-9-CM coding is validated to be 99% accurate by chart review on clinical, laboratory, imaging and endoscopy results . The statistics on liver cancer stratified by age and gender of the general Hong Kong population that were available till year 2016 were extracted from the Hong Kong Cancer Registry, Hospital Authority . The Hong Kong population number over the years stratified by age and gender were extracted from the Hong Kong Census and Statistics Department .
We evaluated all subjects with psychiatric illness first diagnosed between January 1, 2003 and December 31, 2007 in Hong Kong. We selected this period so that the patients would have more than 10 years of follow-up. Psychiatric illnesses were defined by ICD-9-CM diagnosis codes (290.0–319). Patients aged below 18 years old or above 70 years old at the diagnosis of psychiatric illness; had mental retardation; had dementia as the first diagnosed psychiatric illness; HCC or hepatic events before the diagnosis of psychiatric illness; and history of cancer within 5 years before the diagnosis of psychiatric illness were excluded. Patients were grouped as having mood disorders, psychotic disorders, drug-induced mental disorders, alcohol-induced mental disorders, and other psychiatric illnesses according to their diagnoses (Supplementary Table 1); patients might have more than one psychiatric diagnosis and were represented in the corresponding groups in the analysis. Patients were followed until diagnosis of liver-related event, censored at death or the last follow-up date (December 31, 2017), whichever came first. For the comparison to the Hong Kong general population on HCC incidence, patients with psychiatric illness were followed until diagnosis of HCC, censored at death or the last follow-up date (December 31, 2016), whichever came first. The study protocol was approved by the Joint Chinese University of Hong Kong - New Territories East Cluster Clinical Research Ethics Committee.
Data were obtained from CDARS in March 2018. We defined the baseline date as the date of first diagnosis of psychiatric illness. We collected demographic data including gender and date of birth. We also retrieved data on liver and renal biochemistries, hematological parameters, relevant diagnoses and procedures, concomitant drugs, and other laboratory parameters at baseline and during follow-up.
Our primary endpoint was liver-related event, which is a composite endpoint of HCC, hepatic events, and liver-related death. We defined HCC based on diagnosis codes (155.0 – hepatocellular carcinoma and 155.2 – carcinoma of liver), or procedure codes for HCC treatment (Supplementary Table 2). We defined hepatic events based on diagnosis and procedure codes of ascites, spontaneous bacterial peritonitis, variceal bleeding, hepatorenal syndrome, hepatic encephalopathy, liver transplantation, and/or liver-related death (Supplementary Table 2). Chronic hepatitis B (CHB) and chronic hepatitis C (CHC) were defined based on diagnosis codes, virological markers and the use of antiviral treatment (Supplementary Tables 3 and 4). Other liver diseases were defined based on diagnosis codes (Supplementary Table 2).
All statistical analyses were performed using Statistical Product and Service Solutions (SPSS) version 25.0 (SPSS, Inc., Chicago, Illinois), SAS (9.4; SAS Institute Inc., Cary, NC), and R software (3.5.1; R Foundation for Statistical Computing, Vienna, Austria). Continuous variables were expressed as mean ± standard deviation or median (interquartile range [IQR]), as appropriate, while categorical variables were presented as number (percentage). Qualitative and quantitative differences between subgroups were analysed by Chi-square or Fisher’s exact tests for categorical parameters and Student’s t test or Mann-Whitney test for continuous parameters, as appropriate. Cumulative incidence function of HCC with adjustment of competing risk of death was estimated with 95% confidence interval (CI). Cumulative incidence function of liver-related events and liver-related death with adjustment of competing risk of death from other causes were estimated with 95% CI. Expected cumulative incidence of HCC in the general population was estimated by Ederer II method, and compared with cumulative incidence of HCC in patients with psychiatric illnesses estimated by Kaplan-Meier method. Age- and sex-standardized incidence ratio (SIR) of HCC in patients with psychiatric illnesses to the general population was estimated by Poisson model. All statistical tests were two-sided. P value of < 0.05 was taken as statistical significance.
We identified 178,225 patients with psychiatric illness first diagnosed between 2003 and 2007; 72,462 were excluded according to the exclusion criteria, the vast majority due to age. Finally, 105,763 patients were included and analysed (Supplementary Figure 1). At baseline, the mean age was 43.0 ± 13.0 years; 63,614 (60.1%) were female; most patients had normal liver and renal function (Table 1). 67,964 (64.0%), 32,262 (30.5%), 10,321 (9.8%), 6066 (5.7%), 15,848 (15.0%) were diagnosed as mood disorders, psychotic disorders, drug-induced mental disorders, alcohol-induced mental disorders, and other psychiatric illnesses, respectively (Table 2); other psychiatric illnesses mainly included personality disorders, sexual disorders, sleep disorders, and dementia developing during follow-up (Supplementary Table 5).
Liver disease in patients with psychiatric illness
Among 105,763 patients, 8256 (7.8%) patients had known liver diseases; 5028 (4.8%), 1807 (1.7%), 807 (0.8%), 1110 (1.0%) had CHB, CHC, alcohol-related liver disease, and fatty liver, respectively (Supplementary Table 6). Patients with drug-induced mental disorders and alcohol-induced mental disorders were more likely to have known liver diseases (18.1%); the most common liver diseases in these two groups were CHC and alcohol-related liver disease, respectively. In contrast, CHB was the most common chronic liver disease in the other groups, in line with the local epidemiology.
Clinical outcomes of patients with psychiatric illness
At a median (IQR) follow-up of 12.4 (11.0–13.7) years, 1461 (1.4%) patients developed liver-related events (Table 2). The cumulative incidence (95% CI) of liver-related events at 5, 10 and 15 years was 0.7% (0.6–0.7%), 1.1% (1.1–1.2%) and 1.6% (1.5–1.8%), respectively. Patients who had alcohol-induced mental disorders had the highest incidence of liver-related events, followed by patients with psychotic disorders and drug-induced mental disorders (Table 2). The cumulative incidence (95% CI) of liver-related events in patients with alcohol-induced mental disorders at 5, 10 and 15 years was 2.9% (2.5–3.3%), 4.9% (4.4–5.5%) and 6.6% (5.8–7.4%), respectively. The cumulative incidence (95% CI) of liver-related events in patients with psychotic disorders at 5, 10 and 15 years was 0.9% (0.8–1.0%), 1.6% (1.4–1.7%) and 2.1% (1.9–2.4%), respectively. The cumulative incidence (95% CI) of liver-related events in patients with drug-induced mental disorders at 5, 10 and 15 years was 0.7% (0.6–0.9%), 1.4% (1.2–1.7%) and 2.0% (1.7–2.3%), respectively (Fig. 1a). Among 1617 patients who developed dementia after baseline, 84 (5.2%) patients developed liver-related events (Supplementary Table 5); their mean age was 68.0 ± 8.9 years at diagnosis of dementia. Among 1461 patients who developed liver-related events, 892 (61.1%) were diagnosed with any chronic liver diseases before the event. Most patients were diagnosed with CHB, followed by alcohol-related liver disease, CHC, and fatty liver. The remaining 569 (38.9%) patients did not have any diagnosis of chronic liver diseases before liver-related events (Supplementary Table 7).
Patients who developed liver-related events were older and more likely to be male (Table 1). They also had lower baseline platelet count, albumin, total cholesterol, high-density lipoprotein and low-density lipoprotein (LDL)-cholesterol; and higher total bilirubin, alanine aminotransferase, creatinine, fasting glucose, hemoglobin A1c and triglycerides. As expected, they were more likely to have known liver diseases. Patients with liver-related events were more likely to be on hypnotics and anxiolytics as well as antipsychotics, but were less likely to be on antidepressants.
Four hundred and seventy-two (0.4%) patients developed HCC (Table 2). The cumulative incidence (95% CI) of HCC at 5, 10 and 15 years was 0.2% (0.1–0.2%), 0.3% (0.3–0.4%) and 0.6% (0.5–0.6%), respectively. Patients who had alcohol-induced mental disorders had the highest HCC incidence, followed by patients with drug-induced mental disorders and psychotic disorders (Table 2). The cumulative incidence (95% CI) of HCC in patients with alcohol-induced mental disorders at 5, 10 and 15 years was 0.6% (0.4–0.8%), 1.0% (0.8–1.3%) and 1.8% (1.2–2.5%), respectively. The cumulative incidence (95% CI) of HCC in patients with drug-induced mental disorders at 5, 10 and 15 years was 0.2% (0.1–0.3%), 0.5% (0.4–0.6%) and 0.7% (0.6–0.9%), respectively. The cumulative incidence (95% CI) of HCC in patients with psychotic disorders at 5, 10 and 15 years was 0.2% (0.1–0.2%), 0.4% (0.3–0.5%) and 0.6% (0.5–0.8%), respectively (Fig. 1b).
Five hundred and ninety-nine (0.6%) patients died from liver-related causes (Table 2). The cumulative incidence (95% CI) of liver-related death at 5, 10 and 15 years was 0.2% (0.2–0.3%), 0.5% (0.4–0.5%) and 0.7% (0.6–0.7%), respectively. Patients who had alcohol-induced mental disorders had the highest occurrence of liver-related death, followed by patients with psychotic disorders and drug-induced mental disorders (Table 2). The cumulative incidence (95% CI) of liver-related death in patients with alcohol-induced mental disorders at 5, 10 and 15 years was 1.2% (0.9–1.5%), 2.2% (1.8–2.6%) and 2.6% (2.2–3.1%), respectively. The cumulative incidence (95% CI) of liver-related death in patients with psychotic disorders at 5, 10 and 15 years was 0.3% (0.3–0.4%), 0.7% (0.6–0.8%) and 0.9% (0.8–1.0%), respectively. The cumulative incidence (95% CI) of liver-related death in patients with drug-induced mental disorders at 5, 10 and 15 years was 0.3% (0.2–0.4%), 0.6% (0.5–0.8%) and 0.9% (0.7–1.1%), respectively (Fig. 1c).
HCC incidence in patients with psychiatric illness compared to general population
Compared to the general population, patients with psychiatric illness had a higher age- and sex-standardized incidence of HCC (SIR 1.42, 95% CI 1.28–1.57, P < 0.001) (Table 3 and Fig. 2). The difference in age- and sex-standardized incidence of HCC was the most significant in patients with drug-induced mental disorders (SIR 3.18, 95% CI 2.41–4.11, P < 0.001) and alcohol-induced mental disorders (SIR 2.98, 95% CI 2.30–3.81, P < 0.001) when compared to the general population (Supplementary Figure 2A and B). The difference was also significant in patients with psychotic disorders (SIR 1.39, 95% CI 1.16–1.65, P < 0.001) and mood disorders (SIR 1.16, 95% CI 1.00–1.34, P = 0.047) as compared to the general population (Table 3 and Supplementary Figure 2C and D).
Among 472 patients who developed HCC during follow-up, the median age at HCC diagnosis was 61 (range 26–83) years. 140 (29.7%) received curative treatment including liver resection, liver transplantation, and local ablative therapy. Sixty-four (13.6%) patients received transarterial chemoembolization, 19 (4.0%) received target therapy or immunotherapy, and 6 (1.3%) patients received chemotherapy. The remaining 243 (51.5%) patients received supportive care. Among the 472 HCC patients, 367 (77.8%) had known liver diseases. Patients with known liver disease were more likely to receive local ablative therapy than those without known liver disease (11.2% vs. 1.9%, P = 0.004), but there was no difference in the other treatment modalities. Overall, 30.8% of patients with known liver disease and 25.7% of patients without known liver disease received HCC treatments of curative intent (P = 0.315) (Table 4). The median overall survival after HCC diagnosis was 8.0 (95% CI 5.0–10.9) months.
Cause of death in patients with psychiatric illness
Among 105,763 patients, 10,614 (10.0%) patients died during follow-up (Table 2). The leading cause (percentage) of death was infection (18.4%), followed by cancers other than HCC (16.1%), suicide or self-inflicted poisoning (12.2%), and cardiovascular disease (11.5%) (Supplementary Table 8). Liver disease was the fifth leading cause of death in patients with psychiatric illness; 595 (5.6%) patients died due to liver disease (Fig. 3). Infection was the leading cause of death in patients with mood disorders, psychotic disorders, and other psychiatric illnesses, while suicide and self-inflicted poisoning was the leading cause of death in patients with drug-induced mental disorders; cancer excluding HCC was the leading cause of death in patients with alcohol-induced mental disorders. Liver disease was the fifth leading cause of death in patients with mood disorders, psychotic disorders, and other psychiatric illness, while liver disease was the third leading cause of death in patients with alcohol-induced mental disorder, and ranked the sixth in patients with drug-induced mental disorders.
In this large territory-wide study in Hong Kong, we demonstrate that HCC and cirrhotic complications are common in patients with psychiatric illness. Importantly, nearly 40% of patients were never diagnosed to have chronic liver diseases before the development of hepatic complications. While drug- and alcohol-induced mental disorders were associated with a 3-fold increase in HCC risk relative to the general population, the risk was also increased among patients with the common psychiatric conditions of mood disorders and psychotic disorders. Because of the low awareness of liver diseases in this population, the majority of patients with HCC could only receive supportive care.
Some psychiatric illnesses share obvious risk factors with liver diseases. In particular, 13.1% of patients with drug-induced mental disorders had documented history of CHC (Supplementary Table 6). In Hong Kong, 40–50% of injection drug users are chronically infected with hepatitis C virus [3, 26]. Although the diagnosis rate is 50% in the overall community , the diagnosis rate among injection drug users is much lower, and only a quarter of patients diagnosed to have CHC would eventually receive antiviral therapy. It is also noteworthy that the proportion of patients with other psychiatric illnesses who had CHC (0.9–3.3%) was still much higher than the population prevalence of positive anti-hepatitis C virus antibody (0.5%) . This suggests high risk behaviours in some of the other psychiatric patients as well. Similarly, more patients with alcohol-related mental disorders had documented history of alcohol-related liver disease. The proportion of alcohol-related liver disease was relatively low about patients with other psychiatric illnesses (0.4–1.0%). The proportion of excessive alcohol use was also low in the general population .
As expected, the risk of HCC and cirrhotic complications was highest in patients with alcohol-induced mental disorders (5.7%) (Table 2). Nonetheless, 1.0–1.9% of the other psychiatric patients also developed hepatic complications. Although this may not be a high percentage, it is important to note that this incidence of liver-related events is much higher than what is projected from the population prevalence or incidence of advanced liver disease [29,30,31]. In fact, all the common psychiatric illnesses were associated with a higher risk of HCC than the general population (Table 3). Liver disease was the third leading cause of death in patients with alcohol-induced mental disorders and fifth to sixth leading cause of death in patients with other psychiatric illnesses (Fig. 3). In contrast, liver disease is not among the top ten causes of death in the general population . As an analogy, a study in Minnesota suggested that liver disease was the thirteenth leading cause of death in the general population but the third leading cause of death among NAFLD patients . Specific liver assessments and managements are important in high-risk populations, and our study shows an increased risk of hepatic morbidity and mortality in the psychiatric population.
If we agree that psychiatric patients represent a high-risk group for liver diseases, the next question is how to identify patients with liver disorders. The low rate of liver disease diagnosis prior to the development of liver-related complications in our study highlights the importance of improving case finding. For similar reasons, the age at HCC diagnosis was older and the overall survival after HCC diagnosis was shorter in this cohort than other reports from Hong Kong . Previously, our group demonstrated the possibility to detect advanced liver disease by transient elastography in a large number of patients with type 2 diabetes . Previous studies also showed that simple fibrosis scores such as the fibrosis-4 index and aspartate aminotransferase-to-platelet ratio index had high negative predictive values in excluding future liver-related events in the general population . In a United Kingdom model, initial screening by the fibrosis-4 index followed by the enhanced liver fibrosis panel at the primary care setting increased the number of patients detected to have advanced fibrosis by 5 folds . The alternative approach would be to detect specific liver diseases such as through screening for chronic viral hepatitis and alcohol use disorder, followed by evaluation for the severity of liver disease. At present, the implementation of methods to detect advanced liver disease in the psychiatric population has not been tested. The setting for assessment and its uptake as well as the referral pathway need to be addressed in future prospective studies. Since patients with psychiatric illnesses may be on medications that affect liver enzyme levels, the accuracy of simple fibrosis scores in such patients should be evaluated.
Before we have concrete idea about the best way to use the diagnostic tests, the current study provides important data on factors associated with liver-related events (Table 1). Male sex and older age are well known risk factors for HCC and cirrhosis . Thrombocytopenia, hypoalbuminemia, hyperbilirubinemia and high alanine aminotransferase level are markers of cirrhosis and liver injury. Moreover, patients who developed liver-related events had higher fasting glucose and hemoglobin A1c level at baseline. This may suggest that some patients had NAFLD . Alternatively, insulin resistance is also common among patients with cirrhosis . Intriguingly, patients who developed liver-related events also had lower total and LDL-cholesterol. While the exact mechanism is unclear, lipids are involved in the life cycle of hepatitis C virus , and eradication of hepatitis C virus is associated with a rapid increase in serum LDL-cholesterol .
In our study, patients who developed liver-related events were more likely to receive anxiolytics and antipsychotics but less likely to be on antidepressants (Table 1). However, the difference was confounded by indications; patients with different psychiatric illnesses were at risk of different liver diseases. Thus, the association between individual agents and liver-related outcomes was not the primary focus of this study. Previous studies showed that some antidepressants (e.g. nefazodone and trazodone) could cause serious liver injury . On the other hand, a study based on the Taiwan insurance database suggests that users of tricyclic antidepressants and selective serotonin reuptake inhibitors were less likely to develop HCC . While the findings are in keeping with our observation, careful assessment of confounders is required.
The association between psychiatric illness and liver-related complications is likely to be bi-directional. Some liver diseases, notably chronic hepatitis B, likely occurred before the onset of psychiatric illness. Alcohol contributes to psychiatric illness and liver disease simultaneously. NAFLD was probably aggravated by the sedentary lifestyle and obesogenic effect of drug treatments in psychiatric patients. Besides, alcohol use is common in patients with different psychiatric illnesses even though the level may not reach the definition of alcohol use disorder . In NAFLD patients, modest alcohol consumption is associated with increased liver stiffness and a lower chance of histological improvement over time [29, 46].
Our study has the strength of a large sample size, long follow-up duration and the use of territory-wide data representative of the local population. Nonetheless, it also has a few limitations. First, despite the large sample size, a significant proportion of patients with psychiatric illness do not seek medical attention and would not be captured in this study . The cohort is thus more representative of psychiatric patients attending hospital clinics. Second, we included patients with psychiatric diagnoses in 2003–2007, whereas the epidemiology and treatment of chronic liver diseases have changed over the years. However, we also captured treatments and interventions during follow-up until December 2017. Third, although we have laboratory data of the included patients, the database does not include non-invasive tests of liver fibrosis. A prospective study with systematic collection of fibrosis data for this special population would be informative. Fourth, a comparison of cumulative incidence of HCC among patients with psychiatric illnesses and the general population after adjusting the difference in prevalence of hepatitis viral infection and history of alcohol use was not possible due to unavailable data in the general population. In our study, the prevalence of CHC and excessive alcohol use are potentially higher among patients with psychiatric illnesses. Finally, there are notable differences in the epidemiology of liver diseases across countries. Further studies should be conducted to generate data from other regions.
HCC, cirrhotic complications and liver-related deaths are common in psychiatric patients, but liver diseases are often undiagnosed. More efforts are needed to identify liver diseases in the psychiatric population so that treatments and screening for HCC and varices can be provided to patients in need.
Availability of data and materials
The data that support the findings of this study are available from the Hospital Authority, Hong Kong, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the Hospital Authority, Hong Kong.
Clinical Data Analysis and Reporting System
Chronic hepatitis B
Chronic hepatitis C
International Classification of Diseases, Ninth Revision, Clinical Modification
Non-alcoholic fatty liver disease
Standardized incidence ratio
GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1151–210.
Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiat. 2016;3(2):171–8.
Wong VW, Wong GL, Chim AM, Cheng TF, Cheung SW, Lai CM, Szeto KJ, Tsang S, Wu SH, Yan KK, et al. Targeted hepatitis C screening among ex-injection drug users in the community. J Gastroenterol Hepatol. 2014;29(1):116–20.
Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic Steatohepatitis. Hepatology. 2019;69(6):2672–82.
Vilar-Gomez E, Calzadilla-Bertot L, Wong VW, Castellanos M, Aller-de la Fuente R, Metwally M, Eslam M, Gonzalez-Fabian L, Alvarez-Quinones Sanz M, Conde-Martin AF, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018;155(2):443–57 e417.
Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y, Wong VW, Negro F, Yilmaz Y, et al. Nonalcoholic Steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748–55 e743.
Marazziti D, Rutigliano G, Baroni S, Landi P, Dell'Osso L. Metabolic syndrome and major depression. CNS spectrums. 2014;19(4):293–304.
Rojo LE, Gaspar PA, Silva H, Risco L, Arena P, Cubillos-Robles K, Jara B. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res. 2015;101:74–85.
Dashti HS, Follis JL, Smith CE, Tanaka T, Cade BE, Gottlieb DJ, Hruby A, Jacques PF, Lamon-Fava S, Richardson K, et al. Habitual sleep duration is associated with BMI and macronutrient intake and may be modified by CLOCK genetic variants. Am J Clin Nutr. 2015;101(1):135–43.
Chan JW, Lam SP, Li SX, Yu MW, Chan NY, Zhang J, Wing YK. Eveningness and insomnia: independent risk factors of nonremission in major depressive disorder. Sleep. 2014;37(5):911–7.
Fuller BE, Rodriguez VL, Linke A, Sikirica M, Dirani R, Hauser P. Prevalence of liver disease in veterans with bipolar disorder or schizophrenia. Gen Hosp Psychiatry. 2011;33(3):232–7.
Youssef NA, Abdelmalek MF, Binks M, Guy CD, Omenetti A, Smith AD, Diehl AM, Suzuki A. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int. 2013;33(7):1062–70.
Castillo-Sanchez M, Fabregas-Escurriola M, Berge-Baquero D, Fernandez-San Martin M, Boreu QF, Goday-Arno A. Risk of underdiagnosis of hypertension in schizophrenia patients. Clin Exp Hypertens. 2018;40(2):167–74.
van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama. 2012;308(24):2584–93.
Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58(5):1537–47.
Cheng MC, Tong YH, Kwok TC, Cheng IT, Chung AP, Leung JK, Fung MT, Cheung NT. Development Journey of Clinical Data Analysis and Reporting System (CDARS) in Hospital Authority of Hong Kong. MEDINFO. 2010. http://www.meduniwien.ac.at/kpa/publications/MEDINFO_2010_--_Arden-Syntax-Based_Clinical_Decision_Support_Software--Abstract.pdf. Accessed 22 Apr 2020.
The Hospital Authority: Hospital authority statistical report 2012–2013. http://www.ha.org.hk/haho/ho/stat/HASR1415_2.pdf. Accessed 5 Mar 2019.
Man LP, Ho AW, Wong SH. Excess mortality for operated geriatric hip fracture in Hong Kong. Hong Kong Med J. 2016;22(1):6–10.
Wong JC, Chan HL, Tse YK, Yip TC, Wong VW, Wong GL. Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. Aliment Pharmacol Ther. 2017;46(10):1001–10.
Wong GL, Chan HL, Tse YK, Yip TC, Lam KL, Lui GC, Szeto CC, Wong VW. Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. Aliment Pharmacol Ther. 2018;48(9):984–92.
Yip TC, Chan HL, Tse YK, Lam KL, Lui GC, Wong VW, Wong GL. On-treatment improvement of MELD score reduces death and hepatic events in patients with hepatitis B-related cirrhosis. Am J Gastroenterol. 2018;113(11):1629–38.
Lai JC, Wong GL, Yip TC, Tse YK, Lam KL, Lui GC, Chan HL, Wong VW. Chronic hepatitis B increases liver-related mortality of patients with acute hepatitis E: a Territorywide cohort study from 2000 to 2016. Clin Infect Dis. 2018;67(8):1278–84.
Yip TC, Wong GL, Wong VW, Tse YK, Lui GC, Lam KL, Chan HL. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J Hepatol. 2017;68(1):63–72.
Hong Kong Cancer Registry: Cancer Statistics Query Systems. http://www3.ha.org.hk/cancereg/allages.asp. Accessed 15 May 2019.
Census and Statistics Department: Table 002 : Population by Age Group and Sex. https://www.censtatd.gov.hk/hkstat/sub/sp150.jsp?tableID=002&ID=0&productType=8. Accessed 15 May 2019.
Wong GL, Chan HL, Loo CK, Hui YT, Fung JY, Cheung D, Chung C, Chim AM, Wong VW. Hong Kong Association for the Study of liver D: change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy. J Gastroenterol Hepatol. 2019;34(9):1641–7.
Hui YT, Wong GLH, Fung JYY, Chan HLY, Leung NWY, Liu SD, Liu K, Ma YK, But DYK, Mak WY, et al. Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. Liver Int. 2018;38(11):1911–9.
Liu KSH, Seto WK, Lau EHY, Wong DK, Lam YF, Cheung KS, Mak LY, Ko KL, To WP, Law MWK, et al. A Territorywide prevalence study on blood-borne and enteric viral hepatitis in Hong Kong. J Infect Dis. 2019;219(12):1924–33.
Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Woo J, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut. 2012;61(3):409–15.
Wong VW, Wong GL, Yeung DK, Lau TK, Chan CK, Chim AM, Abrigo JM, Chan RS, Woo J, Tse YK, et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol. 2015;62(1):182–9.
Harris R, Harman DJ, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol Hepatol. 2017;2(4):288–97.
Census and Statistics Department: The Mortality Trend in Hong Kong, 1981 to 2015. https://www.statistics.gov.hk/pub/B71612FA2016XXXXB0100.pdf. Accessed 31 May 2019.
Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113–21.
Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(7):1691–700 e1693.
Kwok R, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, Shu SS, Chan AW, Yeung MW, Chan JC, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65(8):1359–68.
Unalp-Arida A, Ruhl CE. Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology. 2017;66(1):84–95.
Srivastava A, Gailer R, Tanwar S, Trembling P, Parkes J, Rodger A, Suri D, Thorburn D, Sennett K, Morgan S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71(2):371–8.
Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28(10):1660–5.
Wong VW, Hui AY, Tsang SW, Chan JL, Wong GL, Chan AW, So WY, Cheng AY, Tong PC, Chan FK, et al. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24(8):1215–22.
Muller MJ, Willmann O, Rieger A, Fenk A, Selberg O, Lautz HU, Burger M, Balks HJ, von zur Muhlen A, Schmidt FW. Mechanism of insulin resistance associated with liver cirrhosis. Gastroenterology. 1992;102(6):2033–41.
Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut. 2010;59(9):1279–87.
Hashimoto S, Yatsuhashi H, Abiru S, Yamasaki K, Komori A, Nagaoka S, Saeki A, Uchida S, Bekki S, Kugiyama Y, et al. Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferon-free treatment. PLoS One. 2016;11(9):e0163644.
Park SH, Ishino R. Liver injury associated with antidepressants. Curr Drug Saf. 2013;8(3):207–23.
Chen VC, Lin CF, Hsieh YH, Liang HY, Huang KY, Chiu WC, Lee Y, McIntyre RS, Chan HL. Hepatocellular carcinoma and antidepressants: a nationwide population-based study. Oncotarget. 2017;8(18):30464–70.
Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on alcohol and related conditions III. JAMA psychiatry. 2015;72(8):757–66.
Ajmera V, Belt P, Wilson LA, Gill RM, Loomba R, Kleiner DE, Neuschwander-Tetri BA, Terrault N. Nonalcoholic Steatohepatitis clinical research N: among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic Steatosis and Steatohepatitis. Clinl Gastroenterol Hepatol. 2018;16(9):1511–20 e1515.
Killaspy H, Banerjee S, King M, Lloyd M. Prospective controlled study of psychiatric out-patient non-attendance. Characteristics and outcome. Br J psychiatry. 2000;176:160–5.
Ethics approval and consent to participate
This study was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee (Ref. No. 2018.230).
The Ethics Committee waived the need for written consent as this was a retrospective study using deidentified registry data.
Consent for publication
This paper does not involve individual participant’s data.
TCFY has served as a speaker for Gilead Sciences. GLHW has served as an advisory committee member for Gilead Sciences, and as a speaker for Abbott, Abbvie, Bristol-Myers Squibb, Echosens, Furui, Gilead Sciences, Janssen and Roche. HLYC has served as an advisory committee member for AbbVie, Aligos, Aptorum, Altimmune, Arbutus, ContraVir, Intellia, Janssen, Gilead, Medimmune, Roche, Vaccitech, VenetoRx, Vir Biotechnology and GRAIL; and as a speaker for AbbVie, Gilead and Roche. VWSW has served as an advisor/consultant for 3 V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Echosens, Gilead Sciences, Janssen, Novartis, Novo Nordisk, Perspectum Diagnostics, Pfizer and Terns; and a speaker for Bristol-Myers Squibb, Echosens, Gilead Sciences and Merck. GLHW, HLYC and VWSW have received research grants from Gilead Sciences. The other authors report no conflict of interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Table S1. ICD-9-CM diagnosis codes involved for patients with other psychiatric illnesses. Table S2. ICD-9-CM diagnosis and procedure codes for hepatic complications, liver cirrhosis, liver transplantation, HCC, and HCC treatment. Table S3. List of viral serological markers retrieved. Table S4. Drug codes of antiviral treatment used in Hospital Authority internally. Table S5. List of liver-related events for each psychiatric illness of the patients in details. Table S6. List of chronic liver diseases in patients with different psychiatric illness. Table S7. List of chronic liver diseases in 1,461 patients with liver-related events. Table S8. Causes of death in patients with psychiatric illness. Figure S1. Study patient flow. Figure S2. Expected cumulative incidence of hepatocellular carcinoma based on population data and observed cumulative incidence of hepatocellular carcinoma in patients with (A) drug-induced mental disorders, (B) alcohol-induced mental disorders, (C) psychotic disorders, and (D) mood disorders with age- and sex-standardization.
About this article
Cite this article
Yip, T.CF., Wong, G.LH., Tse, YK. et al. High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study. BMC Gastroenterol 20, 128 (2020). https://doi.org/10.1186/s12876-020-01277-0
- Liver fibrosis
- Liver neoplasms
- Liver failure
- Mental disorders